Contact Us
+
Years Of Experience
projects successfully completed
+
biologics and innovative products

About Us

RDS Biotech and its partner Acertus has knowledge, expertise, and stellar management gained over the last 30 years in the development and production of biotechnology products. RDS Biotech has behind it a well-trained management team experienced in strategic planning and project execution. Together with Acertus management RDS has in-depth experience and measurable success in the areas of recombinant protein, molecular biology, bacterial and eukaryotic cell fermentation, protein purification derivatization, formulation, filling and package design, sales marketing, and the entire chain from basic to market.

RDS provides Turnkey based solutions, having all end-to-end disciplines under one roof. Allowing a full range of services required to design and execute your new manufacturing facility, resulting in a time efficient, cost effective, tailor-made, highly optimized projects.

Read More
Manage Construction

Lorem ipsum dolor sit amet, conse ctetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore veniam, quis nostrud.

Read More
Technology Transfer

Lorem ipsum dolor sit amet, conse ctetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore veniam, quis nostrud.

Read More
All About Biotechnology Sector

Lorem ipsum dolor sit amet, conse ctetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore veniam, quis nostrud.

Read More
Overview

Our Successes

The group has successfully developed, licensed out, and transferred several technologies to multi-national companies such as Human Insulin and its Analogues, a third-generation hepatitis B vaccine, Human Growth Hormone, GCSF, IFNa2b, Factor VIIa, a diagnostic for Hepatitis C. RDS Biotech provides management and consulting services for its technologies in all aspects. RDS Biotech also provides training and technical support to ensure a successful outcome. RDS Biotech’s strength lies in its ability to meet market needs, its creativity, and its association with major national companies in joint ventures and/or partnerships.

Who We Are

  • Dr. Saul Mashaal

  • Mr. David Mashaal

  • Mr. Reda Benamor

  • Mr. Essam Hammad

  • Mr. Bruce Cohen

  • Dr. Talal Al Zaher

  • Dr. Jacob Hartman

Founder & Director

Founder and Chairman of Acertus Pharma LLC. Founder and Co-Chairman of Valin Technologies and Vanir Pte Ltd. Founder and Chairman of the Scitech Group founded in 1988.

Dr. Mashaal took Scitech Genetics Pte. Ltd., from a start-up to a successful ASX listing. At listing, the portfolio consisted of three Biosimilars and one breakthrough vaccine for immunization against Hepatitis. Building of a biological manufacturing facility with a CAPEX value of US$500 million.

Founder & Director

Mr. Mashaal has over 20 years of experience in biopharmaceutical and pharmaceutical business. Expertise in global business development and deal making with major biotechnology companies. Ability to negotiate, execute and implement distribution, joint venture, technology transfers, and license agreements.

Over 20 years in international experience, with global responsibilities. Experience in M&A, fundraising, in private and public markets. Prior Firms: Scitech Medical, SciGen Ltd, Acertus Pharma.

Founder & Director

Mr. Benamor has over 22 years of experience in process engineering and plant technology. This includes 20 years of worldwide experience related to the engineering design of manufacturing facilities. Project execution and lifecycles. FEED, DED, EPICM for biotechnology, pharmaceutical, and refining projects. Conversant with international codes and practices for biotechnology, pharmaceutical, and refining. Manages and coordinates between different teams to have an optimized and free issues design to meet project schedules. Ensure Compliance with international standards as well as with good engineering practices. QA/QC & Development of Technical Protocols. Prior firms: Nova Engineering France (Technip), Foster Wheeler-Worley Parsons/Exxon UK, Petrofac UK, QP-SASOL

Advisor to Board, Operations

Mr. Hammad has 25 years of experience in multiple disciplines of the Pharma industry including solid dosage forms, liquid dosage forms, sterile manufacturing, lyophilization technology, and biopharmaceutical industry. Experience in the biopharmaceutical industry, including technology transfer and implementation (Bacterial fermentation and mammalian cell culture). Experience with biotech facility setup and project execution, large-scale equipment installation & qualification, process design and scale-up from lab to production scale, production startup, and process validation. Prior firms: Julphar , UAE

Advisor Blood Fractionation

Mr. Bruce Cohen has 30 years of experience in life sciences and high technology. He is a Venture Partner with Xeraya Capital and Senior Advisor at Acertus. He is currently serving as CEO of Statim Pharmaceuticals. Mr. Cohen holds a BA, cum laude, and an MA from Tufts University, as well as an MBA with distinction from Harvard Business School. Prior Firms: Founding President and CEO of Acacia Biosciences, Cellerant Therapeutics and VitaPath Genetics. He also served as CFO at GeneSoft Pharmaceuticals and held senior positions in business development and marketing at Sequus Pharmaceuticals and Baxter.

Chief Scientific Officer

A B.Sc in biology/biochemistry and PhD in molecular biology experienced professional in protein biochemistry, bioindustry, and biopharmaceutics. Experience in molecular biology and protein chemistry including purification, analysis, formulation, stabilization, and modification. Specialized in biosimilar regulatory development as per EMA and other current guidelines for biosimilar approvals and authorization. Worked in R&D for 30 years. Led biosimilar development such as insulin and insulin analogs, erythropoietin, mAbs, and many others.

Chief Medical Officer

Dr. Hartman received a PhD in Molecular Biology and was a post-graduate fellow in the Department of Microbiology and Immunology and Molecular Biology Institute at UCLA. Dr. Hartman was with Biotechnology General Corp. (now Ferring) where he was responsible for biopharmaceutical project development, project evaluation, and strategic planning. Director of R&D at SciGen Ltd, Dr. Hartman was responsible for the comprehensive characterization of Sci-B-Vac, GCSF technology transfer coordination, and validation and support of the manufacturing facility in Pune, India. Instrumental in the development of recombinant human insulin, carboxipeptidase B, interferon’s a and β and PEGylated Uricase Dr. Hartman has 36 publications in first-tier scientific journals and 32 patents.